The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors
| Image |  |
|---|---|
| Description | scientific article published on 16 February 2012 |
| Author/s |
author: Paweł Krawczyk Kamila Wojas-Krawczyk Kinga Winiarczyk Maciej Krzakowski Radosław Mlak Janusz Milanowski Piotr Jaśkiewicz Tomasz Kucharczyk Dariusz M Kowalski |
| Publication date | February 16, 2012 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |